Abstract
Abstract
Background
A pharmacogenomic clinical decision support tool (PGx-CDS) for thiopurine medications can help physicians incorporate pharmacogenomic results into prescribing decisions by providing up-to-date, real-time decision support. However, the PGx-CDS user interface may introduce errors and promote alert fatigue. The objective of this study was to develop and evaluate a prototype of a PGx-CDS user interface for thiopurine medications with user-centered design methods.
Methods
This study had two phases: In phase I, we conducted qualitative interviews to assess providers’ information needs. Interview transcripts were analyzed through a combination of inductive and deductive qualitative analysis to develop design requirements for a PGx-CDS user interface. Using these requirements, we developed a user interface prototype and evaluated its usability (phase II).
Results
In total, 14 providers participated: 10 were interviewed in phase I, and seven providers completed usability testing in phase II (3 providers participated in both phases). Most (90%) participants were interested in PGx-CDS systems to help improve medication efficacy and patient safety. Interviews yielded 11 themes sorted into two main categories: 1) health care providers’ views on PGx-CDS and 2) important design features for PGx-CDS. We organized these findings into guidance for PGx-CDS content and display. Usability testing of the PGx-CDS prototype showed high provider satisfaction.
Conclusion
This is one of the first studies to utilize a user-centered design approach to develop and assess a PGx-CDS interface prototype for Thiopurine Methyltransferase (TPMT). This study provides guidance for the development of a PGx-CDS, and particularly for biomarkers such as TPMT.
Funder
Richard L. Roudebush Veterans Affairs Medical Center
HSR&D
Publisher
Springer Science and Business Media LLC
Subject
Health Informatics,Health Policy,Computer Science Applications
Reference49 articles.
1. NIH. What is pharmacogenomics. 2018. Available from:
https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics
. Cited 2018 10/3.
2. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet. 2003;19(11):660–6.
3. NIH. What is pharmacogenomics. 2017. Available from:
https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics
. Cited 2017 01/09.
4. CPIT. Center for pharmacogenomics and individualized therapy. Available from:
https://pharmacy.unc.edu/research/centers/cpit/
. Cited 2015 02/05.
5. Liu YP, et al. Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. PLoS One. 2015;10(3):e0121745.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献